Silo pharma (silo) and zylo therapeutics, inc. (zti) enter into joint venture agreement to focus on the development of ketamine using zti's z-pod™ technology for the transdermal time released delivery of therapeutics

Sustained transdermal delivery method may be key for alzheimer's and parkinson's patients with dysphagia (difficulty swallowing) sustained transdermal delivery method may be key for alzheimer's and parkinson's patients with dysphagia (difficulty swallowing)
SILO Ratings Summary
SILO Quant Ranking